Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Cohort, Open-label Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)

NCT03267680 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03267680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03267680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Cohort, Open-label Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Terminated
Start date
November 8, 2017
Completion date
March 13, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical squamous cell carcinoma in situ, vulvar high grade squamous intraepithelial lesion